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Summary.-Levamisole, which has immunostimulant activity, is now being used to
treat some forms of cancer. We report that the drug enhances granulocyte colony
formation. The mechanism of action appears to be partly through modulation of
molecules on cell membranes. The molecular content of colony-stimulating activity
(CSA) released into leucocyte-conditioned medium by cells of leukaemic and some
preleukaemic patients can be quantitatively altered by levamisole, both in vitro and
in vivo, but the CSA produced is qualitatively similar to that released by normal
cells. The demonstrated levamisole enhancement of colony formation, and altered
CSA types detected in leucocyte-conditioned medium, makes this drug a promising
candidate for treatment of selected leukaemic states and in preleukaemia.
LEVAMISOLE is a synthetic antihelmin-
thic agent which modulates the immune
response, especially in subjects who have
a compromised immune status. The drug
restores polymorphonuclear, macrophage
and T-cell functions in vitro, and is often
effective in vivo (Symoens & Rosenthal,
1977). Whilst levamisole probably has no
significant therapeutic value in the treat-
ment of patients with advanced cancer
(Ward, 1976), the drug may delay relapse
or the recurrence of metastases in patients
with cancer in remission (Rojas et al.,
1976; Amery et al., 1977). Similar favour-
able responses have been noted in acute
leukaemia in animals (Chirigos et al., 1975)
and humans (Brincker et al., unpublished).
Evidence is also available that levamisole
may favour marrow restoration after
chemotherapy (Lods et al., 1976).
We postulated that the effect of leva-
misole in cancer, and particularly in
leukaemia, might be related to the preser-
vation or stimulation of marrow and
immunological function. We assessed this
postulate by testing the effects of leva-
misole on haemopoietic and lymphatic
progenitor cells in cell culture. We report
the stimulant effect ofthe drug on haemo-
poietic progenitors and also note an
alteration in the release of certain mole-
cules from cells of leukaemic and pre-
leukaemic patients when the cells are
exposed to levamisole.
PATIENTS* AND METHODS
Studies on colony formation
Nineteen adults admitted to hospital for
investigation and treatment of various dis-
orders had peripheral blood and marrow
collected as part of their necessary medical
evaluation.
Control studies (Patients 1-9).-Marrow
was obtained from 9 patients with diverse
medical disorders, none ofthem with evidence
ofleukaemia, preleukaemia or sideroblastosis.
The 2 patients with malignancy had no
inarrow infiltration. Peripheral blood was
obtained from 2 other persons with no
haematological abnormality. MarrowA and
Correspondence: Dr J. S. Senn, Room 2040, Stiiunnybrook Medical Centre, 2075 Bayview Ave, Toronto,
Ontario, Canada, MI4N 3M5.
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peripheral blood from this group of patients
served as "normal" control specimens.
Neutropenia (Patients 10-12).-Marrow and
peripheral blood were obtained from 3 adults
whose neutrophil counts were below 1000/ul.
Acute leukaemia (Patient 20).-A man with
acute myeloid leukaemia had marrow and
blood studies done before any therapy but
after receiving oral levamisone.
Preleukaemia and idiopathic acquired sidero-
blastic anaemia (IASA) (Patients 13-19).-
Four adults with the "preleukaemic syn-
drome" (Linman & Bagby, 1976) and 3
patients with IASA were also studied.
Studies on high-mol. wt colony-stimulating
activity (HMW-CSA)
Five adults admitted for the treatment of
haematological illness had blood collected in
the course of their evaluation, and HMW-
CSA was studied.
Acute leukaemia (Patient 20).
Chronic myeloid leukaemia (CML) (Patient
21). - A patient with a 10-year history ofCML
without medication.
Preleukaemia and IASA (Patients 15-17).-
Two patients with preleukaemia and 1 with
IASA.
Granulocyte colony growth in culture
The assay for granulopoietic colony forma-
tion (CFU-C) in culture was similar to that
of Iscove et al. (1971). Marrow cells were
suspended in methyl cellulose in Alpha
Medium (Flow Laboratories) with 20% foetal
calf serum (FCS) in the presence (or absence)
of20% leucocyte-conditioned medium (LCM).
In some experiments, levamisole 2-4 ,l/ml
(10-5M) was also added in culture; this pro-
duces a concentration of the drug in culture
similar to that achieved in the serum after
an oral dose of 150 mg levamisole (Symoens
& Rosenthal, 1977).
Tests were done on unseparated nucleated
marrow cells or on marrow cells subjected to
an adherence procedure which removes those
cells producing CSA (Messner et al., 1973).
In addition to the above-mentioned tech-
nique, marrow cells were grown in liquid
cultures for 7 days before methyl cellulose
culture, as previously described (Messner
et al., 1974). The cultures contained 20%
(v/v) FCS and LCM at a concentration of
20% (v/v). The cultures were incubated at
37°C and an atmosphere of 7.5% CO2 in air
for 7 days. Aliquots were then plated to
assess the number of granulocyte colony pro-
genitors after culture. In some cases, 10-5M
levamisole was added in liquid culture.
Marrow-cell testings were done on either un-
separated nucleated marrow cells or on non-
adherent marrow cells.
Preparation and testing of high-mol.-wt
colony-stimulating activities (HMW-CSA)
Preparation ofleucocyte-conditioned medium
(LCM).-Heparinized blood leucocytes were
immobilized in 0.5% (w/v) agar, 10% (v/v)
FCS and Alpha Medium at 106 cells/ml. The
agar base was overlaid with an equal volume
of Alpha Medium plus 10% (v/v) FCS at
37°C in a humidified atmosphere of 10% CO2
and air. Overlaid medium was harvested at
7 days and tested for granulocyte CSA
(Iscove et al., 1971). Leucocyte-conditioned
medium was also prepared in the presence
of10-5M levamisole and, after the usual 7-day
incubation, medium was dialysed to remove
low-mol.-wt components, including leva-
misole. The preparation was then used as a
stimulant in the assay for CFU-C.
Purification of HMW-CSA.-CSA from
medium conditioned by human leucocytes
was then purified by the method of Price
et al. (1975). In brief, LCM was treated by
(NH4)28O4 precipitation, DEAE cellulose
chromatographyand hydroxyapatite chroma-
tography. HMW-CSA was then fractionated
by sucrose-gradient sedimentation and as-
sayed.
Assayfor colony-stimulating activity (CSA).
-Testing was done on 2 x 105 non-adherent,
non-leukaemic marrow cells in 0.8% (w/w)
methyl cellulose and Alpha Medium supple-
mented with 20% (v/v) FCS. Portions of the
purified CSA were then added at 20% con-
centration (v/v) for a final volume of 1 ml of
culture per dish, and the dishes were incu-
bated for 14 days in a humidified atmosphere
of 10% CO2 and air. The colonies with >20
cells were then counted.
RESULTS
Granulocyte colony formation (CFU-C) by
bone marrow andperipheral bloodcells*
Normal marrow cells yielded about 20%
more granulocyte colonies (CFU-C) when
* Tables II and III.
42LEVAMISOLE AND HAEMOPOIETIC CELL CULTURE
TABLE II.-Effect oflevamisole on granulo-
cyte colonyformation (CFU-C)
Cultural conditionst
No
Patient Marrow LCM
No. cells* (0)
Controls
1
2
2
3
4
5
7
8
9
9
Neutropenia
10
11
12
Preleukaemia
13
14
15
S
S
T
S
T
T
T
T
S
T
S
T
T
T
T
T
1
0
0
7
93 + 23
23+5
58+5
0
0
32+4
0
43 + 4
14+4
20%
20% LCM+
LCM LMSI
13+1
42
11 + 1
74
130+ 28
38 + 11
88 + 11
2
71+ 11
85+13
7+1
74+14
39+13
27+13
30+14
38+7
100
139 + 23
51 +5
83+2
11
60
97+4
TABLE III.-Effect oflevamisoleon CFU-C
after liquid culture (AC)
Patient
No.
Controls
6+1
93+1
25+16
66+4 148+ 12 159+ 17
5+1 23+7 51+4_
132 119 129
IASA
19 T 1 146 120
AML
20 T 0 17+1 17
* S =Separated, removing adherent cells. T =Un-
separated total marrow.
t Each result is the no. of colonies in 4 plates
(mean+s.d.) each containing 2 x 105 nucleated
marrow cells.
$ 10-5M levamisole.
levamisole was added in culture in the
presence ofLCM. There was no significant
increase in CFU-C when levamisole was
added to cultures without LCM. Marrow
cells from patients with the "preleukaemic
syndrome" yielded a similar 20% increase
in CFU-C in the presence of levamisole
and LCM. In contrast, no increase in
CFU-C number was induced by levamisole
when marrow cells from patients with
acute leukaemia, neutropenia, or sidero-
blastosis were tested.
Marrow cells were then cultured in
liquid culture with or without levamisole
for 7 days, and then assayed with the
usual CFU-C technique. Marrow from all
patient classes tested yielded no sig-
nificant increase in CFU-C after liquid
culture in the presence oflevamisole.
In summary, levamisole in cell culture
yields increased CFU-C by modest pro-
CFU-Ct
in 20%
LCM
Liquid after
Marrow cultural liquid
cells* conditions* culture
4 T 0
LCM
LCM+LMS
5 T 0
LCM
LCM+LMS
6 S 0
LCM
LCM+LMS
8 S 0
LCM
LCMI+LMS
8 T 0
LCM
LCM+LMS
Neutropenia
10 T 0
LCM
LCM+LMS
11 T 0
LCM
LCM+LMS
12 T 0
LCM
LCM+LMS
Preleukaemia
13 T 0
LCM
LCM+LMS
279+ 15
245 + 51
224+6
53 + 5
103+19
140 + 25
19+ 1
130+8
19+ 10
4+ 1
67 + 10
8+2
14+5
62+8
17+5
0
166 + 52
268+ 14
0
160+ 34
202+11
0
72+ 9
69+16
70+2
168 +5
172+5
ACt
3 0
1-9
1-6
2-3
2-7
4-8
0 7
2-2
0 7
0-2
2-0
0-2
0-8
3-4
1*1
11-1
10-3
2-2
2-2
1-8
2-8
1-1
1*2
1*2
* See footnote to Table II.
t 2 x 105 nucleated marrow cells tested after 7-day
culture in liquid medium. (Mean +s.d. for 2-4
replicates.)
$ The ratio of CFU-C after liquid culture to
CFU-C in 20% LCM before liquid culture (Table II).
portions, for both normal marrow cells
and those from preleukaemic patients.
There is no predictable effect on CFU-C
after liquid culture.
Alteration in HMW-CSA
Peripheral blood cells (PBL) from 2
patients with leukaemia and 3 with pre-
leukaemia were cultured to produce LCM
in the presence or absence of levamisole.
The analysis of the components of HMW-
CSA demonstrated one type only in all
patients when LCM was produced in the
usual fashion. However, when levamisole
was added in culture, the cells from all
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TABLE IV.-Effect oflevamisole on HMWI'-
CSA* release
HMW-CSA moieties in medium
No LMS in LMS
Patient No. LMSt cultuire in vivot
20 (AML) 1 3 3
21 (CML) 1 3 ND
13 (Preleukaemia) 1 3 ND
14 ,, 1 3 ND
15 ,, 1 3 ND
* HWM-CSA =High-mol.-wt colony-stimulating
activity.
t LMS =Levamisole.
t One patient only receivedl LMS orally.
patients produced 3 components ofHMW-
CSA. Thus, levamisole causes the cultured
cells of leukaemic and preleukaemic pa-
tients to release into conditioned medium
HMW-CSA similar in type to that released
by normal blood cells (Table IV).
One patient with acute leukaemia was
then given oral levamisole and after 5 days
his peripheral blood cells produced 3
moieties of HMW-CSA, whereas before
oral levamisole it produced only one
component of HMW-CSA. There was no
measurable clinical or haematological im-
provement in this patient (Table IV).
Marrow cells from 4 "control" patients
were then tested for CFU-C using LCM
prepared from the PBL of a single pre-
leukaemic patient; the tests were done
with conditioned medium prepared in the
normal fashion, or in the presence of
levamisole and dialysed. An average in-
crease of 40%o in CFU-C was noted when
control marrow cells were stimulated by
LCM prepared in the presence of levami-
sole, compared with LCM prepared in the
asual way. Ifcells from a normalindividual
were used to prepare LCM, there was no
comparable increase (Table V).
In summary, levamisole in culture per-
mits PBL of leukaemic and preleukaemic
patients to form LCM containing the usual
3 moieties of HMW-CSA. When a leukae-
mic patient was given oral levamisole, his
peripheral produced LCM similar to that
produced by normal PBL (i.e. with 3
HMW-CSA components). Finally, leva-
misole potentiates the release of HMW-
TABLE V.-Effect of HMW4'-CSA types
on CFU-C
Patient
No.
1
6
8
9
PL-l
49
75
13
18
pi
7
9
2
21
CFU-C*
L-3 NL NL-LMS
77 53 49
12
'2
30 28
* CFU-C per 2 x 105 nucleated marrow cells
assayed; average of 2 plates. LCM was prepared
from PBL of Preleukaemia Patient 16. LCM pre-
pared without levamisole contained one moiety of
HMW-CSA (PL-1); LCM prepared with levamisole
10-5M contained 3 components ofHMW-CSA (PL-3).
NL and NL-LMS are LCM prepared from PBL of
a normal donor in the absence or presence of 10-5M
levamisole respectixvely.
CSA components into (conditioned) cul-
ture medium.
DISCUSSION
The mechanism of action of levamisole
on CFU-C is not clear. Levamisole does not
appear to act directly upon granulocyte
colony-forming cells, since its maximal
effect generally appears to be exerted in
the presence of both adherent cells and
leucocyte-conditioned medium (LCM).
These findings are in keeping with the
study of Mahmood & Robinson (1977)
whichsuggestedthatoneeffectoflevamisole
was to enhance CSA production rather
than to influence CFU-C cells directly.
Further understanding of the levamisole
effect is provided by our data, which
indicate that the drug influences the
expression of high-mol.-wt components
of CSA in leucocyte-conditioned medium.
Contrasting the effects of LCM produced
by the cells of a single preleukaemic
patient and containing either I or 3
components of HMW-CSA, it is evident
that the LCM containing 3 components
is considerably more active in promoting
CFU-C. Our findings suggest that CSA
levamisole acts by modulation of CSA,
rather than by acting directly on granulo-
cyte colony-forming cells.
We have previously reported (Price
et al., 1975) that PBL from normal indi-
viduals or patients with leukaemia or
preleukaemia have 3 HMW-CSA com-
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ponents on their cell membranes. How-
ever, LCM produced from normal cells
contains 3 high-mol.-wt components,
whereas we detected only one HMW-CSA
component in LCM produced by cells
obtained from leukaemic and some pre-
leukaemic patients. This abnormality in
HMW-CSA expression may be related to
abnormal release of HMW-CSA from cell
membranes, or to limitations in the detec-
tion ofthese components. The finding that
levamisole causes cells of leukaemic and
preleukaemic patients to express 3 HMW-
CSA components in LCM suggests that
the drug acts at the cell-membrane level,
promoting the release of CSA. The obser-
vation that administration of levamisole
to a leukaemic patient produces a similar
effect on the ability of the patient's cells
to release CSA suggests that the drug
effect is not a cell-culture artefact. In the
single patient tested, there was no increase
in peripheral granulocyte count after 10
days of drug administration (levamisole
was then discontinued because the drug
was poorly tolerated by the patient). We
have studied the release of HMW-CSA in
leukaemic patients treated by metho-
trexate, busulphan or vincristine and pred-
nisone, and have seen that only the usual
single moiety of HMW-CSA was released
by their cells into LCM. This observation
suggests that the levamisole effect on
CSA release is not common to cytotoxic
drugs. In contrast, we have noted that 3
HMW-CSA components are released by
the cells of leukaemic patients when
remission is achieved (Price et al., 1975).
Thus, levamisole alters the CSA release by
cells of leukaemic and some preleukaemic
patients, mimicking the change when
patients with leukaemia reach remission.
Brincker et al. (1976) have noted favour-
able effects from the use of levamisole in
adult acute leukaemia. Lods et al. (1976)
have used levamisole to promote restora-
tion of normal bone marrow function
after chemotherapy. Our findings in cell
culture suggest that some of the beneficial
effect of levamisole in this instance mav
be related to stimulation of haemopoietic
progenitor cells. In view of other known
immunostimulant effects of levamisole,
it may be that the stimulatory effects on
marrow are modulated through a complex
series ofcellular interactions in the haemo-
poietic and lymphoid systems.
The diagnosis of preleukaemia can now
be made with a high degree ofcertainty by
standard clinical and morphological cri-
teria (Pierre, 1974; Linman & Bagby,
1976). The disorder may be slowly pro-
gressive, but once deterioration begins,
outlook is limited and response to the
usual chemotherapeutic agents is poor.
For this reason, the disorder has been
studied intensively, and abnormalities
in cell culture have been noted (Greenberg
et al., 1971; Senn & Pinkerton 1972;
Senn et al., 1976). Linman & Bagby (1976)
reported a favourable response in one
preleukaemic patient which was predicted
in cell culture. The present paper indicates
that levamisole enhances colony forma-
tion and alters a membrane defect in the
cells of some preleukaemic patients. These
cultural findings suggest that levamisole
would be an appropriate agent for thera-
peutic trial in preleukaemic states, which
generally respond poorly to standard
treatment regimens.
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